Disturbed postprandial lipid metabolism in patients with psoriasis: a preliminary report

Year 2020, Volume: 3 Issue: 3, 65 - 68, 30.09.2020

Osman Çağlar Çevik , Buket Akçan Asım Örem Sadık Öztürk Sevgi Bahadır , Savaş Yaylı

Abstract

Not required for letter to editor 1
Not required for letter to editor 2
Not required for letter to editor 3
Not required for letter to editor 4
Not required for letter to editor 5
Not required for letter to editor 6
Not required for letter to editor 7
Not required for letter to editor
8
Not required for letter to editor
9
Not required for letter to editor
10
Not required for letter to editor

Keywords

oral fat tolerance test, psoriasis, lipid metabolism

References

• Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-51.
• Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012;132:556-62.
• Miller IM, Ellervik C, Zarchi KS, et al. The association of metabolic syndrome and psoriasis: a populationand hospital-based cross-sectional study. J Eur Acad Dermatol Venereol 2014:29;490-7.
• Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145:700-3.
• Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ’psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7.
• Vanizor Kural B, Orem A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003;328:71-82.
• Orem A, Cimsit G, Deger O, Orem C, Vanizor B. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis. Clin Chim Acta 1999;284:81-8.
• Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
• Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142-52.
• Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: An Expert Panel statement. Current Vascular Pharmacology 2011;9:258-70.
• Orem A, Ozer Yaman S, Altinkaynak B, et al. Relationship between postprandial lipemia and atherogenic factors in healthy subjects by considering gender differences. Clin Chim Acta 2018;480:34-40.
• Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5.
• Gaeta M, Castelvecchio S, Ricci C, Pigatto P, Pellissero G, Cappato R. Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. Int J Cardiol 2013;168:2282e8.
• Karbach S, Hobohm L, Wild J, et al. Impact of psoriasis on mortality rate and outcome in myocardial infarction. J Am Heart Assoc 2020;9:e016956.